{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-140285","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2025-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.287445+00:00","generated_at":"2026-05-19T08:31:18.724581+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enliven reports 47% cumulative MMR by 24 weeks for ELVN-001 in Phase 1 CML trial; well-tolerated","bullets":["47% of evaluable patients (25/53) achieved MMR by 24 weeks; 32% (13/41) achieved MMR, comparing favorably to asciminib's 24% in Phase 1.","90 patients enrolled; 80% remain on study with median treatment duration ~29 weeks; heavily pretreated (67% received ≥3 prior TKIs).","Safety: only 3.4% dose reductions, 4.6% discontinuations due to AEs; no treatment-related arterial occlusive events; no MTD reached.","PK supports once-daily dosing with food flexibility and low drug-drug interaction potential.","Company expects to initiate first head-to-head Phase 3 pivotal trial in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-140285","json":"https://secwatch.observer/filing/0001193125-25-140285.json","markdown":"https://secwatch.observer/filing/0001193125-25-140285.md","text":"https://secwatch.observer/filing/0001193125-25-140285.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525140285/0001193125-25-140285-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312525140285/d877944d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T08:31:18.724581+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}